SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Mahamaya Lifesciences Ltd

BSE: 544611 NSE: ISIN: INE0U9D01019
  |   Sector:  Chemicals & Fertilizers   |   Industry:  Pesticides & Agrochemicals

Snapshot

Q.1 Which industry/sub-sector does Mahamaya Lifesciences Ltd belong to?
Mahamaya Lifesciences Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Pesticides & Agrochemicals segment.
Q.2 Is Mahamaya Lifesciences Ltd a good quality company?
Mahamaya Lifesciences Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Mahamaya Lifesciences Ltd undervalued or overvalued?
Mahamaya Lifesciences Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Mahamaya Lifesciences Ltd a good buy now?
Mahamaya Lifesciences Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd revenue growth is 63.5% for FY-2025 , which is above its 5 year CAGR of 0% , indicating faster growth.
Q.2 Gross Profit margin of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.2% for FY-2025 , which is above its 5 year median of 6.3% , indicating increasing margins.
Q.3 Operating Profit Margin of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 8.77% for FY-2025 , which is above its 5 year median of 8.03% indicating increasing margins.
Q.4 Net Profit Margin of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Net Profit Margin is 4.85% for FY-2025 , is above with its 5 year median of 3.99%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 7.2 6.3
Operating Profit Margin 8.77 8.03
Net Profit Margin 4.85 3.99
Q.5 Return on Asset of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Return on Asset is 8.51%, which is above its 5 year historical median of 7.04%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Return on equity is 34.17% for FY-2025 , which is above its historical median of 27.53%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Return on capital employed is 26% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Cash conversion cycle is 100 days, above its historical median of 65 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.75 1.87
ROE 34.17 27.53
ROCE 26 23.32
Cash Conversion Cycle 100 days 65 days
Q.9 Debt to Equity ratio of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Debt-to-Equity ratio is 1.16 , which is above with the industry average of 0.27 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Mahamaya Lifesciences Ltd?
Mahamaya Lifesciences Ltd Debt to cash flow from operations is -17.33 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Mahamaya Lifesciences Ltd?
Promoters hold 56.35% of the Mahamaya Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Mahamaya Lifesciences Ltd vs industry peers?
Mahamaya Lifesciences Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 8.45% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 264.2 716.1
Gross Profit 19 68.5
Operating Profit 23 86
Net Profit 13 44
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.75 1.19
ROE 34.17 13.63
ROCE 26 16.98
Cash Conversion Cycle (days) 100.37 93

Valuation & price assessment

Q.1 Stock return of Mahamaya Lifesciences Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -
Q.3 Valuation ratios of Mahamaya Lifesciences Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 31.77 30.29 24.15
Price to Book 3.57 3.40 2.51
Price to Sales 1.54 1.47 1.40
EV to EBITDA 17.62 16.90 12.63

Check more companies

1. Sumitomo Chemical
2. Bayer CropScience
3. Sharda Cropchem
4. Rallis India
5. Dhanuka Agritech
6. NACL Industries
7. Bhagiradha Chem
8. Bharat Rasayan
9. Insecticides India
10. GSP Crop Science
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×